Inari Medical, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Inari Medical, Inc.
LimFlow recently earned FDA approval for its transcatheter deep-vein arterialization system for the treatment of chronic limb-threatening ischemia. Inari, which has previously focused on venous thromboembolism, believes LimFlow's total addressable market could be worth over $4bn annually, with no direct competition in sight.
The company will focus on developing its VenoValve system to treat chronic venous insufficiency and a second product for venous disease.
During the third quarter, device company fundraising totaled $3.3bn; while in vitro diagnostic firms and research tools players raised $3.4bn.
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.